Company* (Country; Symbol) Company* (Country; Symbol) Type/Product Area Terms/Details (Date)
Axela Biosensors Inc.* (Canada) BioCheck Inc.* Licensing and supply agreement for clinical reagents that will be commercialized into biomarker assays on Axela's dotLab System An initial set of research assays will be focused on protein biomarker analysis; Axela intends to further develop those into individual and multiplexed clinical diagnostic panels (5/7)
Bioceros NV* (the Netherlands) CELLution Biotech BV* (the Netherlands) Collaboration to manufacture high levels of recombinant proteins in the disposable CELL-tainer bioreactor Bioceros will use CELL-tainer technology to provide sufficient amounts of recombinant proteins for preclinical testing (5/14)
BioLife Solutions Inc. (OTC BB:BLFS) Intercytex Group plc (UK; LSE:ICX) Supply and licensing agreement for access to BioLife's HypoThermosol storage and preservation media, when used in production of Vavelta and ICX-TRC BioLife is entitled to annual license fees; Vavelta is a facial rejuvenation product and ICX-TRC is a hair regeneration product (5/7)
Enzo Life Sciences (unit of Enzo Biochem Inc.; NYSE:ENZ) Abbott Laboratories (NYSE:ABT) Deal covers the supply of certain Enzo products for use in the Abbott Molecular FISH product line The companies also entered into a limited nonexclusive, royalty-bearing cross-licensing agreement of patents for fluorescence in situ hybridization systems, comparative genomic hybridization analysis and labeling and detection technologies (5/3)
Inno Biologics Sdn. Bhd.* (Malaysia) Malaysian Bio-Diagnostics Research Sdn. Bhd.* (Malaysia) Supply agreement that involves supplies of antibodies from Inno to MBDR for use in diagnostic kits Financial terms were not disclosed (5/10)
Invitrogen Corp. (IVGN) Cytori Therapeutics Inc. (CYTX) Global strategic supply and commercialization agreement to offer adipose-derived stem cell-based research products to life science researchers Invitrogen will offer Cytori's stem cell products to broaden the understanding of adult stem cells and to discover and accelerate development of preclinical applications for adipose-derived stem cells (5/8)
Millipore Corp. (NYSE:MIL) Gen-Probe Inc. (GPRO) Millipore will market Gen-Probe's Mycoplasma Tissue Culture Non-Isotopic test The new agreement expands on the companies' existing collaboration, begun in 2005, to create a new generation of nucleic acid tests (5/7)
Solstice Neurosciences Inc.* Eisai Co. Ltd. (Japan; FSE:EII) Agreement for European commercialization of NeuroBloc injectable solution to treat cervical dystonia The product is known as Myobloc in the U.S. and was approved in the European Union in 2001; Solstice may receive up to $55.7M in up-front and milestone payments (5/15)
Stallergenes SA (France; PARIS:GENP) CMC Biopharmaceuticals A/S* (Denmark) Agreement to develop and supply recombinant Bet v 1 purified bulk CMC will produce batches for Phase III trials and commercial supply of Stallergenes' Oralair (5/14)
Tercica Inc. (TRCA) Lonza Group Ltd.* Manufacturing and commercial supply agreement for Increlex, recombinant human insulin-like growth factor-1 Companies agreed to transfer the manufacture of bulk Increlex from Lonza's Baltimore facility to its Hopkinton, Mass.-based facility (5/16)
Viropro Inc. (Canada; OTC BB:VPRO) Intas Biopharmaceuticals Ltd.* (India) Companies signed a memorandum of understanding for the production of an undisclosed therapeutic protein Intas will invest equity in Viropro, and pay a licensing fee for the development and technology transfer of the manufacturing process; Viropro also gets royalties and both firms will be able to out-license the process, sharing royalties from third-party manufacturers (5/10)
Notes:
* Private companies are indicated with an asterisk.
Unless otherwise noted, stock symbols listed are on the Nasdaq market.
FSE = Franfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board.